BioSight
Companies
CG Oncology, Inc. logo

CGON

NASDAQDALLAS, TX
CG Oncology, Inc.

CG Oncology is developing cretostimogene, an immunotherapy candidate for treating non-muscle invasive bladder cancer (NMIBC) in high-risk and intermediate-risk patients. The product is designed to be administered in a two-step process and is still in clinical development, with the company planning ongoing trials to evaluate its efficacy and tolerability compared to existing treatments.

Price history not yet available for CGON.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar